Richardson, Paul G <br/><br/>
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.  [electronic resource] 

 -  Blood  Nov 2002 
 - 3063-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2002-03-0996  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Combined Modality Therapy<br/>Constipation--chemically induced<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Lenalidomide<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Myeloma Proteins--analysis<br/>Nervous System Diseases--chemically induced<br/>Neutropenia--chemically induced<br/>Peripheral Blood Stem Cell Transplantation<br/>Remission Induction<br/>Safety<br/>Salvage Therapy<br/>Thalidomide--administration & dosage<br/>Thrombocytopenia--chemically induced<br/>Transplantation, Autologous<br/>Treatment Outcome